Search

The hyperglycemia associated with the most commonly prescribed antihypertensive drug classes is of growing concern to the medical community. It is well documented that β-blockers and thiazide diuretics cause adverse metabolic effects, and large-scale studies and meta-analyses provide compelling data indicating that β-blockers and thiazide diuretics increase the risk of diabetes.1–5 The ability to discern which participants are at greatest risk for hyperglycemia associated with β-blockers and thiazide diuretics or the development of diabetes would be valuable to clinicians4,6–9. Previous studies found that African ancestry, higher body mass index, left ventricular hypertrophy, higher follow-up systolic blood pressure, elevated baseline glucose, uric acid, female sex, and age are associated with the development of diabetes after long-term β-blocker and/or thiazide diuretic therapy. 3, 4, 10, 11 One study found that African ancestry, lower baseline glucose, and urinary sodium excretion were significant predictors for change in glucose after hydrochlorothiazide (HCTZ) monotherapy.12 To date, no studies have evaluated predictors for glucose change associated with β-blockers. Given that hyperglycemia and diabetes associated with the use of thiazide diuretics and β-blockers may offset the clinical benefit of these two drug classes,10, 13–15 it is important to identify the clinical characteristics that increase risk. If such factors could be identified, they might be useful to guide selection of antihypertensive therapy. Therefore, the goal of the current study was to determine the clinical characteristics associated with change in glucose and impaired fasting glucose (IFG) following treatment with atenolol or HCTZ.

An altered diurnal blood pressure (BP) pattern has been linked to the risk of developing heart failure (HF). We tested whether an altered diurnal BP pattern is associated with adverse outcomes (death or hospitalization for HF exacerbation) in patients with HF.A total of 118 patients with HF were enrolled from a tertiary care HF clinic and followed for death or HF hospitalization for up to 4 years; 24-hour ambulatory BP was monitored. Forty patients (34%) had a normal BP dipping pattern (night-day ambulatory BP ratio0.9), 44 patients (37%) had a nondipping pattern (0.9or = night-day ambulatory BP ratio1.0), and 34 patients (29%) had a reverse dipping BP pattern (night-day ambulatory BP ratioor = 1.0). A total of 39 patients had an adverse outcome. Adverse outcome rates were the lowest in dippers and the highest in reverse dippers (log rank P = .052). Predictors of adverse outcomes, selected on the basis of log likelihood contrast, were as follows: New York Heart Association functional class (hazard ratio [HR] 1.96, 95% confidence interval [CI] 1.11-3.44), anemia (HR 2.50, 95% CI 1.23-5.08), and dipping status (HR 1.65, 95% CI 1.08-2.50).In addition to other traditional predictors, BP dipping status may be an important prognostic factor in HF.

Objectives. To establish and assess the effectiveness of a 10-week summer research program on increasing doctor of pharmacy (PharmD) students' interest in research, particularly as it related to future career choices. Design. Survey instruments were sent to 25 participants who had completed the research program in the summer of 2004, 2005, or 2006 to assess their satisfaction with the program and its influence on their career choices after graduation. Assessment. Respondents reported a high degree of satisfaction with the program, indicating that the program allowed them to determine their suitability for a career in research, and 55% reported their intention to pursue additional research training. Conclusion. A brief introduction to the clinical research environment helped pharmacy students understand the clinical sciences and careers in research. The introduction increased the likelihood of students pursuing a research career path after obtaining their PharmD degree.